E
PREVAIL trial design - With permission from Medivation and Astellas

Insights on the enzalutamide PREVAIL data pre-chemotherapy in advanced prostate cancer

Medivation and Astellas provided an update at AUA 2014 on the Xtandi PREVAIL data with a breakdown for visceral and non-visceral disease.

May 19, 2014
E
Orlando AUA 2014

AUA 2014 – New targets in prostate cancer

New targets are emerging in advanced prostate cancer that may help improve outcomes and overcome adaptive resistance

May 18, 2014